TITLE:
Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia

CONDITION:
Congestive Heart Failure

INTERVENTION:
Darbepoetin Alfa

SUMMARY:

      The purpose of this study is to evaluate whether weight-based or fixed starting doses result
      in comparable hemoglobin increases and treatment effects in patients with heart failure and
      anemia.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 21 Years to N/A
Criteria:

        Inclusion Criteria: - Symptomatic CHF for at least 3 months - Reduced left ventricular
        ejection fraction - Stable heart failure medication - Hemoglobin concentration between 9.0
        and 12.5 g/dL Exclusion Criteria: - Hypertension - Unstable angina pectoris or recent
        myocardial infarction - Likely to receive cardiac transplant - Major organ transplant
        (e.g., lung, liver, heart) or in renal replacement therapy (e.g., dialysis) - Recent or
        current treatment for malignancy - Systemic hematologic disease - Anemia due to acute or
        chronic bleeding - Recent Epogen or darbepoetin alfa therapy - Recent blood transfusion
      
